Lanreotide Sun

Lanreotide, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It treats acromegaly and neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide is a somatostatin analog used in endocrine disorders.

Acromegaly: reduces excess growth hormone secretion and helps control disease activity. Neuroendocrine tumors: suppresses tumor‑related hormone release and may slow disease progression. Carcinoid syndrome associated with neuroendocrine tumors: helps control flushing and diarrhea symptoms.

Lanreotide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Diarrhea or abdominal cramps - Headache - Hyperglycemia or altered glucose tolerance - Fatigue

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe hyperglycemia requiring medical intervention - Anaphylactic or severe allergic reactions - Cardiac arrhythmias or conduction abnormalities - Hepatic enzyme elevations

Before initiating therapy, clinicians should consider several safety aspects.

Monitor glucose levels: patients with diabetes may experience worsening hyperglycemia. Assess gallbladder status: risk of gallstone development warrants periodic imaging. Evaluate cardiac function: monitor for potential arrhythmias, especially in patients with pre‑existing heart disease. Avoid use in patients with known hypersensitivity to lanreotide or any excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may lower lanreotide plasma concentrations. - Octreotide or other somatostatin analogs: additive hormonal suppression can increase risk of adverse effects. - Antidiabetic agents: may need dose adjustment due to lanreotide‑induced hyperglycemia.

Moderate Interactions (Monitor Closely): - Medications affecting gallbladder motility (e.g., ceftriaxone): monitor for gallstone formation. - Drugs that prolong QT interval: observe cardiac rhythm for additive effects. - Concomitant use of peptide‑based therapies: watch for overlapping side‑effect profiles.